Literature DB >> 35023080

Probable ertapenem-induced encephalopathy; case report and suggested alternatives for chronic prostatitis.

Beatriz Fernández-Rubio1, Rafael Luque-Márquez2, María-Victoria Gil-Navarro3.   

Abstract

Ertapenem is a carbapenem antibiotic usually reserved for complicated infections. Drug-induced neurotoxicity is a rare adverse reaction associated with ertapenem, and may be directly related to its chemical structure. We report a case of a 64-year-old male with a hematological history and chronic prostatitis that was admitted to hospital for gait instability, clumsiness, dysarthria and tremors. He started ertapenem intravenous 1 g once daily a week prior to admission. Creatinine clearance calculation by the Cockcroft-Gault method was 52 mL/min and total protein levels were low. Ertapenem's administration was discontinued and the patient's neurological symptoms improved dramatically just one day after. The result of the Naranjo Scale was six, suggesting a probable adverse drug reaction. We discussed if he could receive meropenem in case of severe infection such as septic shock. Considering the patient's medical history, the chemical structure of meropenem and the fact that there are almost no reported cases of neurotoxicity from this drug, we assume that meropenem could be used in case of severe infection in patients with history of neurotoxicity caused by ertapenem if no added risk factors are present, such as renal failure.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Encephalopathy; Ertapenem; Meropenem; Neurotoxicity

Mesh:

Substances:

Year:  2022        PMID: 35023080      PMCID: PMC9114266          DOI: 10.1007/s40199-021-00425-5

Source DB:  PubMed          Journal:  Daru        ISSN: 1560-8115            Impact factor:   4.088


  16 in total

1.  Delayed recovery from ertapenem induced encephalopathy: case-report and a possible mechanism.

Authors:  Yat-fung Shea; Ming-yee Maggie Mok; Ka-chun Cheng; Fong-kwong Sonny Hon; Leung-wing Chu
Journal:  Int J Clin Pharm       Date:  2013-06-26

2.  Meropenem delirium: a previously unrecognized neurologic side effect.

Authors:  Sigridh Munoz-Gomez; Arthur Gran; Burke A Cunha
Journal:  J Chemother       Date:  2014-02-27       Impact factor: 1.714

Review 3.  Antibiotic-induced epileptic seizures: mechanisms of action and clinical considerations.

Authors:  Pitchaya Wanleenuwat; Nanthushan Suntharampillai; Piotr Iwanowski
Journal:  Seizure       Date:  2020-08-14       Impact factor: 3.184

Review 4.  Two decades of imipenem therapy.

Authors:  A C Rodloff; E J C Goldstein; A Torres
Journal:  J Antimicrob Chemother       Date:  2006-09-22       Impact factor: 5.790

5.  Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Authors:  Vicki L Collins; Dror Marchaim; Jason M Pogue; Judy Moshos; Suchitha Bheemreddy; Bharath Sunkara; Alex Shallal; Neelu Chugh; Sara Eiseler; Pragati Bhargava; Christopher Blunden; Paul R Lephart; Babar Irfan Memon; Kayoko Hayakawa; Odaliz Abreu-Lanfranco; Teena Chopra; L Silvia Munoz-Price; Yehuda Carmeli; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

6.  Development and implementation of a pharmacist-managed outpatient parenteral antimicrobial therapy program.

Authors:  Eun Kyoung Chung; Cole B Beeler; Eva W Muloma; Danielle Osterholzer; Kendra M Damer; Sharon M Erdman
Journal:  Am J Health Syst Pharm       Date:  2016-01-01       Impact factor: 2.637

7.  A case series of confusional states and other neurotoxic effects caused by ertapenem.

Authors:  Immaculada Danés; Eulàlia Pérez; Carles Pigrau; Rosa M Gracia; Manel Perelló; Maria Sueiras; Cristina Aguilera; Antònia Agustí
Journal:  Br J Clin Pharmacol       Date:  2020-11-03       Impact factor: 4.335

8.  Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients.

Authors:  Lama M Hsaiky; Francine D Salinitri; Judy Wong; Sin-Ling T Jennings; Neha H Desai; Alison M Lobkovich; Raymond Cha
Journal:  Nephrol Dial Transplant       Date:  2019-10-01       Impact factor: 5.992

9.  Risk factors associated with the development of seizures among adult patients treated with ertapenem: A matched case-control study.

Authors:  Yi-Chien Lee; Yun-Jhong Huang; Miao-Chiu Hung; Sheng-Che Hung; Chih-Yen Hsiao; Hui-Ling Cho; Li-Fen Lai; Show-Hwa Tong; Jann-Tay Wang
Journal:  PLoS One       Date:  2017-07-31       Impact factor: 3.240

10.  Ertapenem-Induced Encephalopathy in a Patient With Normal Renal Function.

Authors:  S Scott Sutton; Mark Jumper; Sean Cook; Babatunde Edun; Michael D Wyatt
Journal:  J Investig Med High Impact Case Rep       Date:  2017-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.